WORLD HEALTH ORGANIZATION

The Sickle Cell Disease Market, valued at 3.54 USD Billion in 2022, is projected to grow to 12.56 USD Billion by 2032, with a CAGR of 13.5%. Growth is driven by rising prevalence, advancements in gene therapy, and increased awareness. Key trends include precision medicine, digital health technologies, and patient-centered care, with significant opportunities in gene editing and targeted therapies.

WHO promotes public access to its datasets on data.who.int, compiled from Member States' data, under specific Terms and Conditions. Use of data, including via APIs, requires compliance with these terms and a Creative Commons Attribution 4.0 International License, with disputes resolved through conciliation or arbitration.

2023 was a year of significant events globally and in the U.S., including the end of the COVID-19 emergency, major political shifts, and cultural milestones. Key Bay Area stories included Dianne Feinstein's death, the Oakland A's move, a mass shooting in Half Moon Bay, and the conviction of Sam Bankman-Fried. The year also saw the APEC conference in San Francisco and ongoing protests over the Israel-Hamas war.

The Johns Hopkins Center for Health Security selected 30 professionals for its 2024 Emerging Leaders in Biosecurity Initiative fellowship, from a record 350 applicants. This 11th-year program connects rising biosecurity leaders across sectors, supported by a 300+ alumni network.

The FDA warned nine online pet suppliers, including Chewy, against selling unapproved antimicrobial drugs, contributing to antimicrobial resistance. These drugs, also used in human medicine, are making infections more dangerous. Suppliers have 15 days to comply or face legal action. Antimicrobial resistance is a growing global health threat, with significant human and animal impacts.

The 2020 WHO report highlights cancer's global burden, emphasizing prevention, management, and policy needs. In Ghana, despite a 2011 National Strategy for Cancer Control, challenges persist, with breast and cervical cancers being major concerns. Lifestyle changes and late diagnosis worsen outcomes. Policy advancements are crucial for better prevention, screening, and treatment access.

Leishmaniasis, caused by protozoan parasites transmitted by female phlebotomine sandflies, affects millions globally, with 350 million at risk. It manifests as visceral, cutaneous, or mucocutaneous forms, each with distinct symptoms and impacts. Treatment challenges include drug resistance, toxicity, and the need for new therapies. Vector control and chemotherapy are primary strategies, but socio-economic factors complicate prevention and treatment efforts.

Australia faces high antibiotic consumption and increasing bacterial resistance, risking future medical procedures. Experts urge smarter prescribing to combat this serious health challenge, emphasizing the need for action against unnecessary use to prevent a bleak future of untreatable infections.